<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="367407">
  <stage>Registered</stage>
  <submitdate>12/11/2014</submitdate>
  <approvaldate>27/11/2014</approvaldate>
  <actrnumber>ACTRN12614001243606</actrnumber>
  <trial_identification>
    <studytitle>Comparison between the synergistic use of oral contraceptives and fluoxetine vs fluoxetine alone in the management of premenstrual syndrome </studytitle>
    <scientifictitle>Comparison between the synergistic use of oral contraceptives and fluoxetine vs fluoxetine alone in the management of premenstrual syndrome </scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil known
</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Premenstrual syndrome
</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Menstruation and menopause</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>210 women with premenstrual syndrome (PMS) will be prospectively diagnosed. Diagnosis will be done using the daily record of severity of problems (DRSP), women will be asked to fill the diary for 2 months. Only women with 30% increase in the DRSP score in the week before menses in both months will be diagnosed as having PMS.
Women will be randomly divided into 3 groups, group 1 will receive combined oral contraceptives (gynera) tablets, 75mg Gestodene and 0.03mg ethinylestradiol per tablet orally once daily for 21 days starting starting from the second day of menstruation in addition to the continuous use of fluoxetine (Prozac) oral tablets 50mg daily, the second group will receive continuous fluoxetine oral tablets 50mg daily and the third group will receive a placebo daily. Treatment will be continued for 3 months in all the groups. Monitoring of adherence to treatment will be monitored by asking the patients to return the empty tablet strips.Symptoms of premenstrual syndrome will be assesses 3 months after starting the treatment </interventions>
    <comparator>Placebo Starch tablets</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Changes in the DRSP score. This will be assessed by comparing the DRSP before starting treatment and that 3 months after starting treatment.</outcome>
      <timepoint>3 months after starting the treatment </timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Side effects of oral contraceptives.
All women will be asked to report potential oral contraceptives side effects like vomiting, headache, intermenstrual bleeding, chloasma, weight gain and breast tenderness.</outcome>
      <timepoint>3 months after starting the treatment
</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Fluoxetine side effects.
Women will be asked to report potential fluoxetine side effects like anorexia, insomnia and drowsiness</outcome>
      <timepoint>3 months after starting the treatment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Age 20-40 years
Premenstrual syndrome
Nulligravida</inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>40</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Diabetes
Hypertension
Liver disease
History of DVT
Allergy to fluoxetine </exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>All women with premenstrual syndrome will be invited to participate in the study and asked to sign an informed consent, allocation will be done using sealed envelopes containing computer generated random numbers allocating the patient to a study group</concealment>
    <sequence>Computer generated random numbers </sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>single centre randomized, balanced allocation, parallel groups study</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods>This is the first study to investigate the role of the synergistic use of oral contraceptives and fluoxetine in premenstrual syndrome according to our knowledge. There are no available data to calculate the sample size. This will be a pilot study and we may suggest further studies with larger sample sizes at the end of the study
Data will be presented in the form of means and standard deviations or frequencies and proportions when appropriate. Categorical data will be compared using ANOVA test and non categorical data will be compared using chi square test or exact test when appropriate </statisticalmethods>
    <masking1>True</masking1>
    <masking2>False</masking2>
    <masking3>False</masking3>
    <masking4>False</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>5/05/2013</anticipatedstartdate>
    <actualstartdate>5/05/2013</actualstartdate>
    <anticipatedenddate>5/01/2015</anticipatedenddate>
    <actualenddate />
    <samplesize>210</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Egypt</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Cairo university </primarysponsorname>
    <primarysponsoraddress>1 Alsaraya street
Almanial
Cairo
Egypt
11559</primarysponsoraddress>
    <primarysponsorcountry>Egypt</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Cairo University</fundingname>
      <fundingaddress>1 Alsaraya street
Almanial 
cairo
Egypt
11559
</fundingaddress>
      <fundingcountry>Egypt</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Cairo university hospitals</sponsorname>
      <sponsoraddress>Kasr alainy
1 Alsaraya street
AlManial
Cairo
Egypt
11559</sponsoraddress>
      <sponsorcountry>Egypt</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>210 women with premenstrual syndrome will be randomly divided into 3 groups: group 1 will receive combined oral contraceptives and fluoxetine, group 2 will receive fluoxetine only, and group 3 will receive a placebo.
The change in symptoms will be compared among the groups using DRSP.</summary>
    <trialwebsite />
    <publication>Yonkers KA, Pearlstein TB, Gotman N: A pilot study to compare fluoxetine, calcium And placebo in the management of premenstrual syndrome. J Clin Psychopharmacol. 2013 Oct;33(5):614-20. 

Dickerson LM, Mazyck PJ, Hunter MH: premenstrual syndrome.
Am Fam Physician. 2003 Apr 15;67(8):1743-52. 

Wichianpitaya J, Taneepanichskul S: A comparative efficacy of Low dose combined oral contraceptives containing desogestrel and Drospirenone in premenstrual symptoms.
Obstet Gynecol Int. 2013;2013:487143




</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes>DRSP is the main tool used for diagnosis of PMS and comparing groups. DRSP file is attached below. </publicnotes>
    <ethicscommitee>
      <ethicname>Obstetrics and gynecology ethical committee </ethicname>
      <ethicaddress>department of Obs&amp;Gyn 
Cairo university hospitals
1 Alsaraya street,
AlManial
Kasr AlAiny
Cairo
Egypt,
11559</ethicaddress>
      <ethicapprovaldate>1/05/2013</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Egypt</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment>
    <filepath>http://www.anzctr.org.au/AnzctrAttachments/367407-DRSP.pdf</filepath>
  </attachment>
  <contacts>
    <contact>
      <title>Dr</title>
      <name>AbdelGany Hassan</name>
      <address>Cairo university hospitals
Kasr AlAiny
1 Alsaraya street,
AlManial
Cairo
Egypt
11559</address>
      <phone>+20 010 17801604</phone>
      <fax />
      <email>abdelgany2@gmail.com</email>
      <country>Egypt</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>AbdelGany Hassan</name>
      <address>Cairo university hospitals
Kasr AlAiny
1 Alsaraya street,
AlManial
Cairo
Egypt
11559</address>
      <phone>+20 010 17801604</phone>
      <fax />
      <email>abdelgany2@gmail.com</email>
      <country>Egypt</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>AbdelGany Hassan</name>
      <address>Cairo university hospitals
Kasr AlAiny
1 Alsaraya street,
AlManial
Cairo
Egypt
11559</address>
      <phone>+20 010 17801604</phone>
      <fax />
      <email>abdelgany2@gmail.com</email>
      <country>Egypt</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>AbdelGany Hassan</name>
      <address>60 Fostat apartments 
First neighborhood 
Cairo
Egypt</address>
      <phone>+20 010 17801604</phone>
      <fax />
      <email>abdelgany2@gmail.com</email>
      <country>Egypt</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>